During the last session, ProQR Therapeutics N.V (NASDAQ:PRQR)’s traded shares were 0.39 million, with the beta value of the company hitting 0.22. At the end of the trading day, the stock’s price was $3.62, reflecting an intraday gain of 0.28% or $0.01. The 52-week high for the PRQR share is $4.62, that puts it down -27.62 from that peak though still a striking 67.4% gain since the share price plummeted to a 52-week low of $1.18. The company’s market capitalization is $373.60M, and the average intraday trading volume over the past 10 days was 0.68 million shares, and the average trade volume was 1.35 million shares over the past three months.
ProQR Therapeutics N.V (PRQR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.33. PRQR has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.14.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
ProQR Therapeutics N.V (PRQR) registered a 0.28% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.28% in intraday trading to $3.62, hitting a weekly high. The stock’s 5-day price performance is -5.24%, and it has moved by 4.93% in 30 days. Based on these gigs, the overall price performance for the year is 151.39%. The short interest in ProQR Therapeutics N.V (NASDAQ:PRQR) is 0.68 million shares and it means that shorts have 0.21 day(s) to cover.
The consensus price target of analysts on Wall Street is $3.75, which implies an increase of 3.47% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $5 respectively. As a result, PRQR is trading at a discount of -38.12% off the target high and 44.75% off the low.
ProQR Therapeutics N.V (PRQR) estimates and forecasts
Statistics show that ProQR Therapeutics N.V has underperformed its competitors in share price, compared to the industry in which it operates. ProQR Therapeutics N.V (PRQR) shares have gone up 92.55% during the last six months, with a year-to-date growth rate less than the industry average at 10.53% against 17.90. In the rating firms’ projections, revenue will increase 124.14% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.22M as predicted by 3 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 9.07M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 6.79M and 5.02M respectively. In this case, analysts expect current quarter sales to shrink by -67.33% and then jump by 80.55% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.74%. While earnings are projected to return 3.72% in 2024.
PRQR Dividends
ProQR Therapeutics N.V is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 3.63 million shares, is of ADAGE CAPITAL PARTNERS GP, L.L.C.’s that is approximately 4.4446% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.02 million.
Also, the Mutual Funds coming in first place with the largest holdings of ProQR Therapeutics N.V (PRQR) shares are Delaware Group Equity Fds IV-Delaware Healthcare Fund and Fidelity NASDAQ Composite Index Fund . Data provided on Jun 30, 2024 indicates that Delaware Group Equity Fds IV-Delaware Healthcare Fund owns about 620.0 shares. This amounts to just over 0.76 percent of the company’s overall shares, with a $2.24 million market value. The same data shows that the other fund manager holds slightly less at 46.67, or about 0.06% of the stock, which is worth about $0.17 million.
